201 results about "Hyperglycemias" patented technology

The invention discloses a hexapeptide with a hypoglycemic effect as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The amino acid sequence of the hexapeptide is Ile-Trp-Asp-Pro-His-Phe, and the amino acid sequence of the hexapeptide is as shown in the specification. The novel hexapeptide IWDPHF with prominent DPP-IV inhibition ability is successfully identified from mulberry leaf proteolysis products through liquid chromatography-mass spectrometry and a virtual screening method, the hexapeptide IWDPHF shows the blood glucose reducing effect superior to that of part of known peptides in an in-vitro enzyme activity inhibition experiment and a zebra fish hyperglycemia model, and no obvious side effect exists; the compound has a good potential of being developed into a hypoglycemic functional product or a drug lead compound. The invention further provides the mulberry leaf peptide with the peptide fragment IWDPHF, and the mulberry leaf peptide can be applied to preparation of drugs or food for reducing blood sugar. The invention provides a new scheme and theoretical basis for treatment of diabetes, and has good market prospect and application potential.

Diabetes is a disease characterized by high levels of blood glucose. It is important to keep diabetes under control to avoid short- and long-term complications. Diabetes can affect vision due to the alterations it produces in the blood vessels of the retina. This is known as Diabetic Retinopathy (DR), which is one of the leading causes of impaired vision in developed countries. One of the complications of diabetic retinopathy is Diabetic Macular Edema (DME), which is the leading cause of vision loss in diabetic patients and can appear at any stage of diabetic retinopathy. This consists of the gradual accumulation of fluid in the macula, the most important area of the retina. The determination of diabetic macular oedema is very important for the retina. The determination of diabetic macular oedema is very important for adequate treatment of this condition. A variety of technological options are used for detecting diabetic retinopathy, although only the most sophisticated detect macular oedema, a complication that appears as a consequence of diabetic retinopathy and is one of the leading causes of blindness. The invention describes a portable system for detecting diabetic macular oedema by capturing a fundus image using a portable ophthalmoscope; said image is sent via wired or wireless means to an embedded system that has an algorithm based on artificial intelligence, which extracts information from the image and processes same to identify the presence of the condition being studied.

The present invention discloses modified-release bilayer tablets consisting of two layers, layer 1 consisting 500 mg sustained release metformin and layer 2 consisting 250 mg normal release metformin and 5mg / 10mg delayed-release dapagliflozin. This formulation is meticulously designed to regulate blood glucose levels effectively over an extended period. Immediate-release metformin swiftly addresses acute glucose spikes, while sustained-release metformin ensures prolonged glucose control, minimizing fluctuations throughout the day. The delayed-release dapagliflozin component allows for controlled and timed release, managing persistent hyperglycemia synergistically with metformin. By optimizing efficacy and minimizing glucose fluctuations, this innovative formulation offers a promising solution for stable glycemic control in individuals with diabetes. Present invention aims to improve patient outcomes and enhance overall quality of life by maintaining stable glucose levels and reducing the risk of complications associated with uncontrolled diabetes.

Bromocriptine citrate administered to a vertebrate, animal or human, can be used for any purpose including, e.g., the long-term modification and regulation of metabolic disorders, including prediabetes, obesity, insulin resistance, hyperinsulinemia, hyperglycemia and type 2 diabetes mellitus (T2DM) and / or, e.g., the treatment of other medical disorder(s) including immune or endocrine disorders or diseases. Bromocriptine citrate is administered over a limited or extended period at a time of day dependent on re-establishing the normal circadian rhythm of central dopaminergic activity of healthy members of a similar species and sex. Insulin resistance, hyperinsulinemia and hyperglycemia, T2DM, prediabetes, MS or all, can be controlled in humans on a long term basis by such treatment inasmuch as the daily administration of bromocriptine citrate resets neuronal activity timing in the neural centers of the brain to produce long term effects.

The invention discloses an agaric polypeptide VR5 with alpha-glucosidase inhibitory activity and a preparation method and application thereof, and belongs to the technical field of small molecule peptides. The amino acid sequence of the auricularia auricula polypeptide VR5 is VGMLR, and the auricularia auricula polypeptide VR5 can be prepared by a solid-phase synthesis method and an enzymolysis method (flavourzyme). The agaric polypeptide VR5 has the beneficial effects that experiments prove that the agaric polypeptide VR5 has very high alpha-glucosidase inhibitory activity, IC50 is equal to 34.96 mu g / mL, the agaric polypeptide VR5 can be used as an alpha-glucosidase inhibitor for preventing or treating alpha-glucosidase mediated diseases, and the agaric polypeptide VR5 can be used for preventing or treating alpha-glucosidase mediated diseases. Or as a hypoglycemic active component, the composition is added into auxiliary hypoglycemic functional food for auxiliary regulation of the blood sugar level of hyperglycemia people.

The invention relates to the technical field of non-invasive monitoring, in particular to a diabetes blood glucose fluctuation trend prediction method based on foot temperature and humidity change, which comprises the following steps: continuously collecting temperature, humidity and motion data of multiple areas of a foot through a foot wearable device, extracting a feature set related to blood glucose fluctuation from the preprocessed data, and calculating the blood glucose fluctuation trend according to the feature set; and fusing the feature set and context event information, inputting the fused feature set and context event information into a multi-task deep learning prediction model, visually displaying a prediction result in the forms of a trend arrow, a probability interval and a risk level, and triggering early warning in advance when a hyperglycemia or hypoglycemia event is predicted to be about to occur. The method is completely noninvasive and high in compliance, prospective trend prediction can be carried out based on existing diabetic foot monitoring wearable equipment, individual physiological characteristics of a user can be continuously learned through a built-in personalized self-adaptive mechanism, dynamic calibration is carried out on the model through incremental learning, and the prediction accuracy is improved. And the prediction precision is continuously improved along with the use time.

The invention provides a recognition and early warning method and device for irritable hyperglycemia, electronic equipment and a storage medium, and is applied to the technical field of medical data processing. According to the method, data type information (including FreeStyle LibreH dynamic blood glucose and glycosylated hemoglobin data), influence factor data (improved and preset irritable hyperglycemia index and the like) and abnormal state information (fasting interference and detection difference) are taken; acute-stage and chronic-stage average blood glucose basic data are generated through preprocessing. The index weight is enhanced and improved by means of a dynamic fusion engine, the probability is predicted by combining space-time correlation analysis and binary logistic regression, and the abnormal characteristics are obtained by comparing the difference of the AUC by adopting Delog test. The multi-modal features are processed to obtain an identification result, clinical indexes screened by LASSO are fused, index differences are compared to generate risk influence factors, finally, a dynamic early warning result is generated based on a space-time correlation early warning engine and a multi-target strategy, and accurate identification and early warning are achieved.

The invention relates to the technical field of biological medicines, in particular to application of Amomum villosum Lour. In preparation of products for preventing and / or improving symptoms related to obesity and glucose and lipid metabolism disorder. The symptoms comprise hyperglycemia level, cardiovascular and cerebrovascular diseases, cognitive impairment and the like. The result shows that the fructus amomi can effectively reduce the blood sugar level, obviously inhibit the rise of low-density lipoprotein, improve the cognitive function and regulate the lipid metabolism balance. Based on good glycolipid metabolism regulation activity, fructus amomi can be used for improving hyperglycemia, cardiovascular and cerebrovascular diseases, related cognitive function decline and other symptoms caused by abnormal glycolipid metabolism.

The invention discloses an FAM20B protein and application of an FAM20B protein inhibitor in prevention or treatment of glucolipid metabolism related diseases. Specifically, the invention discloses an application of an FAM20B protein and / or an FAM20B gene in regulation and control of liver glycolipid metabolism. The invention also discloses application of the FAM20B inhibitor in improving, preventing or treating liver glycolipid metabolism disorder or glycolipid metabolism related diseases (such as diabetes, metabolism related fatty liver disease MAFLD, obesity and the like). Experiments show that the FAM20B inhibitor can reduce the liver gluconeogenesis level, relieve impairment of glucose tolerance, relieve hyperglycemia of diabetic patients, reduce the fat content of the whole body and the liver, relieve liver lipid deposition, promote energy consumption, reduce food intake, promote fat burning and reduce liver fat accumulation; the compound can be used for preparing medicines for preventing and treating glucose and lipid metabolism disorder or glucose and lipid metabolism related diseases, and has a wide application prospect in the fields of prevention and treatment of metabolism related diseases.

This invention belongs to the field of diagnostic testing technology. Addressing the problem that existing gestational diabetes screening methods may miss the optimal time for early intervention, leading to the failure to promptly detect and manage some potentially hyperglycemic pregnant women, increasing the risk of adverse maternal and fetal outcomes, this invention proposes a plasma metabolic biomarker for the early diagnosis or prediction of gestational diabetes and its application. This plasma metabolic biomarker is at least one of L-lysine, propargylglycine, N6-acetyl-L-lysine, cyclic leucine, and glycine-deoxycholic acid. The five plasma metabolic biomarkers provided by this invention can be applied to the early diagnosis or prediction of gestational diabetes, and are of great significance for the prevention or treatment of gestational diabetes.

A diabetes management system optimizes glucoregulatory hormone delivery using a connected glucoregulatory hormone delivery system and a computing device with a processor and non-transitory memory. The system receives glucose management data (glucose, insulin delivery, heart rate, or carbohydrate consumption data) from sensors. A digital twin metabolic model is selected and initialized based on the received data. The system simulates diabetes treatment interventions to predict glucose dynamics and determines an optimized glucoregulatory hormone parameter (e.g., insulin dose or increment that minimizes hyperglycemia and hypoglycemia risk). The determined glucoregulatory hormone parameter is transmitted to the connected glucoregulatory hormone delivery system, which may include an automated insulin delivery (AID) system or a connected insulin pen system, for implementation. By integrating real-time physiological data with predictive metabolic modeling, the system enhances glucoregulatory hormone therapy, providing personalized adjustments to improve glucose control.

A composition for use in a method of providing sustained energy release over time in a subject is described. The composition comprises or consists of microparticles comprising high glycaemic index (GI) carbohydrate contained within a gastric-resistant, ileal-sensitive, GLP-1 stimulative, non-porous carrier configured for release of the high GI carbohydrate in the ileum, wherein the composition is administered orally to the subject.

Disclosed herein is a method for treating, preventing, and / or slowing the progression of various chronic inflammatory condition groups including: (1) the Type 2 Diabetes group (Metabolic Syndrome (MET), obesity, hyperglycemia); (2) ARDS (Acute Respiratory Distress Syndrome); (3) chronic autoimmune inflammatory conditions (Rheumatoid Arthritis (RA), Lupus, and Psoriasis); (4) inflammatory bowel diseases (IBD), such as Crohn's disease and ulcerative colitis; (5) metabolite group-mediated diseases (atherosclerosis, hypertension, and congestive heart failure); and (6) eating disorders, such as Prader-Willi Syndrome and other monogenic and symptomatic obesity disorders including leptin pathway defects, each method comprising orally administering a pharmaceutical composition comprising a denatonium salt. The present disclosure is based on the results of a series of studies that tracked biomarker cluster levels to track mediators of inflammatory conditions and mediators of gut signaling hormones in response to orally administered denatonium salts.

Compositions are disclosed that include at least one protein disulfide isomerase or a biologically active fragment or variant thereof. Methods of producing and using the compositions are also disclosed. In particular (but not by way of limitation), methods are provided for reducing blood glucose, treating hyperglycemia, treating or reducing the occurrence of type 1 diabetes, treating or reducing the occurrence of type 2 diabetes, and / or treating or reducing the occurrence of type 3 diabetes (i.e., Alzheimer's Disease) by administering the composition that includes the at least one protein disulfide isomerase. The protein disulfide isomerase may be administered alone or may be administered simultaneously or sequentially with one or more additional active agents.

The invention relates to a metal ion-doped osteogenesis nano enzyme and application thereof, and belongs to the technical field of biological medicines. The metal ion-doped osteogenesis nano-enzyme is prepared by partially replacing iron ions in crystal lattices of the Prussian blue nano-enzyme with active metal ions by utilizing the open type crystal structure characteristic of the Prussian blue nano-enzyme. On the premise of keeping the original catalytic performance of the Prussian blue nano enzyme, the osteogenic nano enzyme can endow a material with a new biological activity function, so that the diabetic bone microenvironment is accurately regulated, and the bone tissue regeneration in a hyperglycemia environment is powerfully promoted. The osteogenic nano-enzyme is integrated into a PCL (polycaprolactone) scaffold, so that the scaffold can be endowed with strong osteoinduction, anti-oxidation and anti-inflammatory functions, and a good foundation is laid for application of the osteogenic nano-enzyme in diabetic bone regeneration.

This invention discloses an octapeptide derived from soybean protein with the function of lowering blood pressure, blood sugar, and cholesterol, as well as its preparation and application, belonging to the field of small molecule peptide technology. The octapeptide sequence is YEGNWGPL, which can be obtained artificially or by targeted enzymatic hydrolysis of soybean protein isolate. Functional verification in a hyperlipidemia model shows that the octapeptide YEGNWGPL has the function of lowering blood lipids; functional verification in a hyperglycemia model shows that the octapeptide YEGNWGPL has the function of lowering blood sugar, with a significantly better effect than the drug metformin; functional verification in a hypertension model shows that the octapeptide YEGNWGPL has the function of lowering blood pressure, with a significantly better effect than the antihypertensive drug captopril; moreover, food-derived bioactive peptides have high biosafety, therefore, they can be applied to the development of related products for lowering blood pressure, blood sugar, and cholesterol or assisting in lowering blood pressure, blood sugar, and cholesterol, with good market prospects and application potential.

Bromocriptine citrate administered to a vertebrate, animal or human, can be used for any purpose including, e.g., the long-term modification and regulation of metabolic disorders, including prediabetes, obesity, insulin resistance, hyperinsulinemia, hyperglycemia and type 2 diabetes mellitus (T2DM) and / or, e.g., the treatment of other medical disorder(s) including immune or endocrine disorders or diseases. Bromocriptine citrate is administered over a limited or extended period at a time of day dependent on re-establishing the normal circadian rhythm of central dopaminergic activity of healthy members of a similar species and sex. Insulin resistance, hyperinsulinemia and hyperglycemia, T2DM, prediabetes, MS or all, can be controlled in humans on a long term basis by such treatment inasmuch as the daily administration of bromocriptine citrate resets neuronal activity timing in the neural centers of the brain to produce long term effects.

Exemplary embodiments account for differing needs of a user over the menstrual cycle of the user to better control the blood glucose concentration of the user. The exemplary embodiments may be realized in control systems for medicament delivery devices that deliver medicaments, such as medicaments that regulate blood glucose concentration levels. Examples of such medicaments that regulate blood glucose concentration levels include insulin, glucagon, and glucagon peptide-1 (GLP-1) agonists. The exemplary embodiments are able to better tailor the dosages of the medicament delivered to the user with the medicament delivery device to reduce the risk of hyperglycemia and hypoglycemia and help reduce blood glucose concentration excursions.

This invention discloses a traditional Chinese medicine composition and its preparation method for treating liver, kidney, and cardiovascular diseases, relating to the field of traditional Chinese medicine preparations. It is made from the following raw materials in parts by weight: 10-30 parts of Gastrodia elata, 15-40 parts of Salvia miltiorrhiza, 10-25 parts of Panax quinquefolius, 10-30 parts of Panax notoginseng, 5-20 parts of Chrysanthemum morifolium, and 10-15 parts of Gecko. This traditional Chinese medicine composition and its preparation method for treating liver, kidney, and cardiovascular diseases features synergistic innovation in formulation, is suitable for specific populations, and achieves the therapeutic effects of clearing liver heat, promoting blood circulation, nourishing qi and yin, and tonifying the liver and kidneys. The process preserves the active ingredients, is suitable for absorption by middle-aged and elderly individuals, and maximizes the retention of heat-sensitive active ingredients such as gastrodin, total saponins of Panax notoginseng, tanshinone IIA, and total flavonoids of Chrysanthemum morifolium. The dosage form is flexible and adaptable, with a wide range of applications. Both the ultrafine powder and oral liquid preparations avoid irritating components. The application is clearly targeted, with significant differentiated advantages, especially suitable for middle-aged and elderly men around 70 years old and individuals with hyperglycemia and dizziness.

Doses and dosing regimens for incretin analogs are disclosed comprising determining and administering doses of long-acting incretin analogs suitable for once-weekly dosing, such as a glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon (GCG) (GGG) tri-receptor agonist.

The invention belongs to the technical field of food additives, and particularly discloses dictyophora rubrovolvata beta-glucan low-calorie hydrophilic colloid and a preparation method and application thereof.The dictyophora rubrovolvata beta-glucan in dictyophora rubrovolvata is extracted through a water extraction and alcohol precipitation method, and the extract has good physiological activities such as blood sugar lowering activity and immunity. And compounding the dictyophora rubrovolvata beta-glucan and erythritol through a series of steps of sol dissolving, decocting and cooling, so as to prepare the dictyophora rubrovolvata beta-glucan low-calorie hydrophilic colloid. The prepared dictyophora rubrovolvata beta-glucan low-calorie hydrophilic colloid is applied to preparation of low-calorie soft sweets, the situation that traditional soft sweets with gelatin as a gelling agent are low in nutritional value and rich in saccharides, and the risk of chronic diseases such as obesity, decayed teeth, hyperglycemia and type II diabetes mellitus can be possibly increased is broken through, and the prepared dictyophora rubrovolvata beta-glucan low-calorie hydrophilic colloid has the advantages of being simple in preparation process, low in cost and the like. And a development direction is provided for researching and developing a novel functional gelling agent into soft sweets.

The invention relates to associated faecalis and application thereof, the associated faecalis is preserved in Guangdong Microbial Culture Collection Center on November 10, 2025, and the preservation number is GDMCC No: 67255. The strain is high in self-aggregation capability, beneficial to adhesion to intestinal tracts and high in customization capability; the strain shows a good safety characteristic and has relatively strong gastrointestinal tract environment adaptability; the strain has remarkable antioxidant activity; the strain can generate gamma-aminobutyric acid, is helpful for improving the metabolic state of a host and regulating the neurological function, and has the probiotic effects of regulating lipid, resisting inflammation and improving the metabolic state of the host, namely improving sleep; besides, the bile salt hydrolase of the strain is remarkable in activity, contributes to bile acid metabolism and promotion of cholesterol excretion, has the effects of reducing and regulating blood fat, and can improve obesity, hyperglycemia, hyperlipidemia and non-alcoholic fatty liver disease.

This invention provides a polypeptide or a pharmaceutically acceptable salt thereof that may be useful in the treatment of type 2 diabetes (T2D), diabetes mellitus with obesity, obesity, and hyperlipidemia. [Solution] Provides a long-acting glucagon-like peptide-1 and a human glucose-dependent insulin secretion-stimulating polypeptide (GIP) biagonal agonist polypeptide.

Disclosed herein are compounds of formula (I): (I), or a pharmaceutically acceptable salt thereof. Also disclosed herein is a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable additive. Further disclosed herein is a method for preventing or treating a disease or condition through the modulation of the glucagon receptor using a compound of formula (I), or a pharmaceutically acceptable salt thereof.

The present application belongs to the technical field of sugarcane leaf polysaccharide regulating intestinal flora. The present application provides a sugarcane leaf polysaccharide composition, which comprises mannose, rhamnose, glucuronic acid, galacturonic acid, glucose, galactose, xylose, arabinose and fucose in a mass ratio of 6.8:1.5:5.2:40.7:13.1:18.9:1.6:6.1:1.9. The composition of the present application can improve the imbalance of intestinal flora caused by obesity and hyperglycemia by reducing the ratio of Firmicutes / Bacteroidetes and increasing the abundance of probiotics.

The invention discloses substitutional tea with effects of preventing hypertension, hyperglycemia, hyperlipidemia and gastric cancer. The substitutional tea is prepared from the following raw materials in parts by mass: 0.8 to 1.2 parts of rhizoma zingiberis, 0.8 to 1.2 parts of poria cocos, 0.8 to 1.2 parts of cortex cinnamomi, 0.8 to 1.2 parts of pericarpium citri reticulatae, 0.3 to 0.7 part of liquorice root, 0.8 to 1.2 parts of rice, 0.8 to 1.2 parts of wheat, 0.08 to 0.12 part of radix ginseng and 0.08 to 0.12 part of folium perillae. The invention develops a tea substitute drink with a prevention effect aiming at the rejuvenation current situation of people with hypertension, hyperlipidemia, hyperglycemia and chronic gastritis. The tea substitute drink has the characteristics of being convenient to brew and convenient to produce, and is easy to use by consumers and easy to produce by manufacturers. The components are easy to absorb, and the prevention effect can be better achieved. Meanwhile, the product is clean and environment-friendly, the burden on the environment is reduced, and the cost performance is high. By adopting the concept of homology of medicine and food, the tea is suitable for people with hypertension, hyperlipidemia and chronic gastritis to drink daily and provides a new choice for preventing related diseases.

The invention discloses a pharmaceutical composition for improving glucose and lipid metabolism disorder by combining N-p-coumaroyl octoamine and rotundine and application of the pharmaceutical composition, and belongs to the field of biological medicine and metabolic disease treatment. In a db / db diabetic mouse model, it is found that NTPC (10 mg / kg) or ROT (10 mg / kg) single drugs can improve hyperglycemia and insulin resistance and reduce blood fat, and low-dosage combination (5 mg / kg of NTPC and 5 mg / kg of ROT) shows the most significant metabolism improvement effect which is obviously better than that of a single drug group. In an in-vitro fatty acid stimulation model, lipid accumulation in cells can be more remarkably reduced through combination of the two drugs, and fatty acid synthesis genes are inhibited.

The present invention discloses a method for alleviating gastrointestinal side effects resulting from the administration of pharmaceutical agents selected from the group including non-steroidal anti-inflammatory drugs (NSAIDs), glucagon-like peptide-1 (GLP-1) receptor agonists, gastric inhibitory polypeptide (GIP) receptor agonists, dual GIP / GLP-1 receptor co-agonists, and combinations thereof, by administering a composition containing colostrum product, bovine colostrum, or combinations thereof to a subject. The present invention discloses compositions and kits related to alleviating gastrointestinal side effects resulting from the administration of pharmaceutical agents selected from a group including non-steroidal anti-inflammatory drugs (NSAIDs), glucagon-like peptide-1 (GLP -1) receptor agonists, gastric inhibitory polypeptide (GIP) receptor agonists, dual GIP / GLP -1 receptor co-agonists, and combinations thereof. This method provides a novel approach to mitigate gastrointestinal side effects associated with the use of these pharmaceutical agents, enhancing patient comfort and compliance during treatment.